Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611075 | 0.92 | GNAO1 (0.34) | NCF1GNAO1DRD2CYP1A2HTR1A | |
| SCHEMBL20234869 | 0.91 | NCF1 (0.34) | NCF1ACHEGNAO1SIGMAR1GNAI3 | |
| SCHEMBL13007658 | 0.86 | CYP1A2 (0.44) | GNAO1SIGMAR1HRH3CYP1A2 | |
| SCHEMBL14081460 | 0.86 | NCF1 (0.50) | NCF1ACHEGNAO1SIGMAR1GNAI3 | |
| SCHEMBL20317545 | 0.85 | GNAO1 (0.31) | GNAO1SIGMAR1DRD2CYP1A2HTR1A | |
| SCHEMBL17282109 | 0.85 | NCF1 (0.38) | NCF1ACHESIGMAR1HRH3 | |
| SCHEMBL13007653 | 0.85 | CYP1A2 (0.47) | SIGMAR1HRH3CYP1A2 | |
| SCHEMBL22924570 | 0.84 | NCF1 (0.48) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL24453221 | 0.83 | GNAO1 (0.35) | ACHEGNAO1CYP1A2 | |
| SCHEMBL23594410 | 0.82 | VCP (0.43) | SIGMAR1HRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, ESRRA, ESR1 | NCF1 3156/4885ACHE 1691/4885GNAO1 1293/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NCF1 3127/4885ACHE 1236/4885GNAO1 1566/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NCF1 3127/4885ACHE 1236/4885GNAO1 1566/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | NCF1 3127/4885ACHE 1236/4885GNAO1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.